The PDGFD Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast cell line, targeting the PDGFD gene. This loss-of-function model provides a genetically modified pool of cells in which PDGFD expression has been disrupted, enabling investigation of PDGFD-dependent signaling networks without the selection of a single clonal isolate. The polyclonal format captures the heterogeneity of editing outcomes across the population, offering a robust tool for studying gene function in a physiological context relevant to B-cell biology.
Raji cells are a well-established human Burkitt lymphoma B lymphocyte cell line, widely used as a model for B-cell malignancies and for antigen presentation studies. Derived from an African Burkitt lymphoma, Raji cells exhibit characteristics of mature B cells and are permissive for efficient gene editing. Their transformed phenotype and rapid proliferation make them a valuable host for dissecting oncogenic signaling pathways, particularly those involving receptor tyrosine kinases and downstream mitogenic cascades. The introduction of a PDGFD knockout in this background allows researchers to explore the interplay between growth factor signaling and lymphomagenesis.
PDGFD encodes platelet-derived growth factor D, a secreted ligand that binds specifically to the PDGFR-beta receptor tyrosine kinase. Ligand binding induces receptor dimerization and autophosphorylation, recruiting the adaptor protein GRB2 and activating downstream RAS-MAPK and PI3K-AKT signaling cascades. Key effectors include MAP2K1 (MEK1), MAPK3 (ERK1), AKT1, and mTOR, which collectively promote cell proliferation, survival, and migration. Transcription of PDGFD is regulated by TGF-beta, HIF-1alpha, and SP1, while PDGFD activity leads to the transcriptional induction of targets such as JUN, FOS, MYC, CCND1, and VEGFA. Interacting factors like integrins and heparan sulfate proteoglycans modulate signaling output.
In the context of Raji B lymphoblasts, PDGFD knockout provides a powerful system to dissect the contribution of PDGFR-beta-mediated signals to B-cell lymphoma biology. The Raji line is characterized by high MYC expression due to a chromosomal translocation, and PDGFD-driven pathways may converge on MYC regulation through MAPK and AKT effectors. Disruption of PDGFD is expected to attenuate these proliferative and survival signals, potentially impairing cell cycle progression and enhancing susceptibility to apoptosis. This model thus allows researchers to investigate how extracellular growth factor cues integrate with intrinsic oncogenic drivers in B-cell neoplasms, and to explore the role of PDGFD in tumor microenvironment interactions and angiogenesis.
These polyclonal knockout cells are ideal for studying PDGF signaling in B-cell lymphoma contexts. Researchers can assess pathway activity by Western blotting for phospho-ERK and phospho-AKT, quantify target gene expression via RT-qPCR, and analyze protein interactions by co-immunoprecipitation of PDGFR-beta complexes. Functional consequences of PDGFD disruption can be examined using proliferation, apoptosis, and migration/invasion assays, complemented by flow cytometric cell cycle profiling. The model supports drug target validation, angiogenesis research, and stromal interaction studies. For additional information, please contact Ascent Research.
